These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8606749)

  • 1. Conformationally constrained peptide drugs targeted at the blood-brain barrier.
    Davis TP; Abbruscato TJ; Brownson E; Hruby VJ
    NIDA Res Monogr; 1995; 154():47-60. PubMed ID: 8606749
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.
    Malakoutikhah M; Teixidó M; Giralt E
    J Med Chem; 2008 Aug; 51(16):4881-9. PubMed ID: 18666771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
    Adenot M; Merida P; Lahana R
    Chemotherapy; 2007; 53(1):73-6. PubMed ID: 17202815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.
    Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP
    J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable.
    Taylor EM; Otero DA; Banks WA; O'Brien JS
    J Pharmacol Exp Ther; 2000 Oct; 295(1):190-4. PubMed ID: 10991978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and design of peptides as a new drug delivery system for the brain.
    Demeule M; Régina A; Ché C; Poirier J; Nguyen T; Gabathuler R; Castaigne JP; Béliveau R
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1064-72. PubMed ID: 18156463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide and peptide analog transport systems at the blood-CSF barrier.
    Smith DE; Johanson CE; Keep RF
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1765-91. PubMed ID: 15381333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the use of cell-penetrating peptides for medical and biological applications.
    Fonseca SB; Pereira MP; Kelley SO
    Adv Drug Deliv Rev; 2009 Sep; 61(11):953-64. PubMed ID: 19538995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography.
    Kai J; Nakamura K; Masuda T; Ueda I; Fujiwara H
    J Med Chem; 1996 Jun; 39(13):2621-4. PubMed ID: 8691461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.
    Poduslo JF; Curran GL; Haggard JJ; Biere AL; Selkoe DJ
    Neurobiol Dis; 1997; 4(1):27-34. PubMed ID: 9258909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration.
    Taylor EM; Otero DA; Banks WA; O'Brien JS
    J Pharmacol Exp Ther; 2000 May; 293(2):403-9. PubMed ID: 10773009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.
    Rousselle C; Smirnova M; Clair P; Lefauconnier JM; Chavanieu A; Calas B; Scherrmann JM; Temsamani J
    J Pharmacol Exp Ther; 2001 Jan; 296(1):124-31. PubMed ID: 11123372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of peptide and protein drugs over the blood-brain barrier.
    Brasnjevic I; Steinbusch HW; Schmitz C; Martinez-Martinez P;
    Prog Neurobiol; 2009 Apr; 87(4):212-51. PubMed ID: 19395337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure.
    Banks WA; Tschöp M; Robinson SM; Heiman ML
    J Pharmacol Exp Ther; 2002 Aug; 302(2):822-7. PubMed ID: 12130749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
    J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The blood-brain barrier is not a "barrier" for many drugs.
    Fenstermacher JD
    NIDA Res Monogr; 1992; 120():108-20. PubMed ID: 1501680
    [No Abstract]   [Full Text] [Related]  

  • 17. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse.
    Nonaka N; Shioda S; Niehoff ML; Banks WA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):948-53. PubMed ID: 12750431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro models for the blood-brain barrier.
    Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
    Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
    Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
    J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.